PMA device
Interstim System
Medtronic Neuromodulation · Implanted Electrical Device Intended For Treatment Of Fecal Incontinence (QON, Class III) · First FDA decision Aug 25, 2011, newest Aug 25, 2011Fecal incontinence and constipation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
43
Naming "Interstim"
MAUDE reports
56,748
Brand "Interstim", since 2015
PubMed studies
226
Mentioning "Interstim"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Interstim System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- INTERSTIM SYSTEMPMA supplement
P080025-S013 · Decided Aug 25, 2011 · 44 days after receipt · Normal 180 Day Track No User Fee
Device type: Implanted electrical device intended for treatment of fecal incontinence (QON) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Sacral Nerve Stimulation for the Treatment of Urinary and Fecal IncontinenceLocal determinationIn effectL39543Palmetto GBAUpdated Sep 12, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Electrical Aversion Therapy for Treatment of AlcoholismNational determinationOn the books130.4Updated Jun 10, 2020
- Biofeedback Therapy for the Treatment of Urinary IncontinenceNational determinationOn the books30.1.1Updated Sep 24, 2015
- Home Health-Surface Electrical Stimulation in the Treatment of DysphagiaLocal determinationIn effectL34565Palmetto GBAUpdated Nov 21, 2023
- Surface Electrical Stimulation in the Treatment of DysphagiaLocal determinationIn effectL34578Palmetto GBAUpdated Aug 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Interstim", any status and sponsor, newest update first.
Odense University HospitalAcademic, hospital or other
NCT05380856 · 60 participants (planned) · Start Aug 18, 2023 · Primary completion Sep 1, 2027
Device: Turning ON the neuromodulator; Turning OFF the neuromodulator · For: Neurogenic Dysfunction of the Urinary Bladder; Multiple Sclerosis; Sacral Neuromodulation and 3 more
Sites: Odense, Denmark
42 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Interstim", and for the whole product code for context.
This brand
56,748 reports: 29,940 malfunction, 26,786 injury, 20 death
Whole product code QON
10 reports: 3 malfunction, 7 injury, 0 death
Newest reports for this brand
- InterStim XInjury
MEDTRONIC PUERTO RICO OPERATIONS CO.
3004209178-2026-18518 · Received Oct 30, 2026 · Event dated Mar 1, 2026
Device type: Stimulator, Electrical, Implantable, For Incontinence (EZW)
Device problem as coded: Migration or Expulsion of Device; Inappropriate/Inadequate Shock/Stimulation; Positioning Problem; Patient Device Interaction Problem
Patient problem as coded: Pain; Electric Shock; Insufficient Information
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Enhanced Verify Evaluation Handset (CFN HH90130FA)Open, Classified
Z-1704-2025 · Started Apr 3, 2025 · Posted by FDA Apr 30, 2025
Reason given: Evaluation handsets may not be able to communicate with the neurostimulator due to handsets having a faster processing speed than prior handsets. An inability to connect may cause the therapy to stop being delivered and a system error will be displayed. Patient may experience return of underlying disease symptoms...
Cause as FDA categorized it: Device Design · Device type: Stimulator, Electrical, Implantable, For Incontinence (EZW)
4 more recall records with a free account
Published research
The most relevant PubMed records for "Interstim"[tiab]. The summary above synthesizes these.
- Neuromodulation.
Noblett K, Crowder C · Obstet Gynecol Clin North Am · 2021Review
- InterStim.
Gardner D · Urol Nurs · 2011Letter, Comment
- Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems.
Meng L, Tian Z, Zhang Y, et al. · Sci Rep · 2022Research Support, Non-U.S. Gov't
- Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
Chartier-Kastler E, Normand LL, Ruffion A, et al. · Eur Urol Focus · 2022Observational Study, Multicenter Study
- Outcomes associated with Interstim therapy for medically refractory fecal incontinence.
McNevin MS, Moore M, Bax T · Am J Surg · 2014Evaluation Study
- Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function.
Powell CR · Curr Urol Rep · 2018Review
- Sacral nerve stimulation: Interstim therapy.
Peeren F, Hoebeke P, Everaert K · Expert Rev Med Devices · 2005Review
- Sacral Neuromodulation: Standardized Electrode Placement Technique.
Matzel KE, Chartier-Kastler E, Knowles CH, et al. · Neuromodulation · 2017
- Sacral neuromodulation with the InterStimࡊ system for faecal incontinence: results from a prospective French multicentre observational study.
Meurette G, Siproudhis L, Leroi AM, et al. · Colorectal Dis · 2021Multicenter Study, Observational Study
- Sacral Neuromodulation with the InterStimࡊ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Chartier-Kastler E, Le Normand L, Ruffion A, et al. · Eur Urol Focus · 2021Multicenter Study, Observational Study
- Retrospective study of sacral neuromodulator implantations in a French hospital center: Lifespan and hospital costs assessment.
Daikh A, Reymond F, Lombardo D, et al. · Int J Colorectal Dis · 2023
- InterStim Therapy: A Contemporary Approach to Overactive Bladder.
Kohli N, Patterson D · Rev Obstet Gynecol · 2009
Other devices of this type
Also filed under product code QON.
- Axonics Sacral Neuromodulation SystemBoston Scientific Corporation · PMA 2026
- InterStim Therapy System, Verify Evaluation SystemMedtronic Neuromodulation · PMA 2025
- InterStim® Sacral Nerve Stimulation Therapy System / Bowel ControlMedtronic Neuromodulation · PMA 2018
- Verify Evaluation System for Interstim Therapy for Urinary Control and Bowel ControlMedtronic Neuromodulation · PMA 2015
- Test Stimulation Lead Bulk Accessory,test Stimulation Lead KitMedtronic Neuromodulation · PMA 2013
- Model 3058 Interstim II NeurostimulatorMedtronic Neuromodulation · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.